IL-7-specific inhibition of spontaneous apoptosis (▵N) in leukemic cells from T-ALL patients
| . | Prednisone response . | P . | |
|---|---|---|---|
| Good . | Poor . | ||
| Total | |||
| ΔN (%) n (pts) | 12.5 ± 1.9 53 | 7.8 ± 2.1 29 | 0.10 |
| TcRγ/δ+ | |||
| ΔN (%) n (pts) | 13.7 ± 3.4 6 | 20.0 ± 6.9 7 | 0.45 |
| TcRγ/δ− | |||
| ΔN (%) n (pts) | 12.4 ± 2.1 47 | 3.9 ± 0.8 22 | 0.02 |
| . | Prednisone response . | P . | |
|---|---|---|---|
| Good . | Poor . | ||
| Total | |||
| ΔN (%) n (pts) | 12.5 ± 1.9 53 | 7.8 ± 2.1 29 | 0.10 |
| TcRγ/δ+ | |||
| ΔN (%) n (pts) | 13.7 ± 3.4 6 | 20.0 ± 6.9 7 | 0.45 |
| TcRγ/δ− | |||
| ΔN (%) n (pts) | 12.4 ± 2.1 47 | 3.9 ± 0.8 22 | 0.02 |
T-ALL patients were subgrouped according to expression of TcRγ/δ and response to initial therapy (prednisone response). The in vivo response was evaluated by blast counting in peripheral blood after the 7-day prednisone prephase and 1 dose of intrathecal methotrexate on day 1. Good and poor response was defined by 1000 blasts/μL peripheral blood cut-off criterion.